Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) has confirmed its total issued share capital as of April 30, 2021, consisting of 494,343,020 ordinary shares of 1 pence each, with no shares held in treasury. This total represents the number of voting rights available to shareholders and serves as a denominator for notifications regarding changes in shareholding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Positive

• Total issued share capital confirmed at 494,343,020 shares.
• Shareholders have a clear denominator for reporting shareholding changes.

Negative

• None.

LONDON, UK / ACCESSWIRE / April 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30 April 2021 consists of 494,343,020 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 494,343,020.

The figure of 494,343,020 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/643467/Hemogenyx-Pharmaceuticals-PLC-Announces-Total-Voting-Rights

FAQ

What is the total issued share capital for Hemogenyx Pharmaceuticals as of April 30, 2021?

The total issued share capital for Hemogenyx Pharmaceuticals as of April 30, 2021, is 494,343,020 ordinary shares of 1 pence each.

How many voting rights does Hemogenyx Pharmaceuticals have?

Hemogenyx Pharmaceuticals has a total of 494,343,020 voting rights.

What does the total number of shares represent for shareholders of HOPHF?

The total number of shares represents the denominator for calculations that shareholders must make to notify changes in their interests under the Financial Conduct Authority's rules.